Abstract | OBJECTIVE: METHODS: A total of 943 patients with primary progressive multiple sclerosis were randomized to GA or placebo (PBO) in this 3-year, double-blind trial. The primary end point was an intention-to-treat analysis of time to 1- (entry expanded disability status scale, 3.0-5.0) or 0.5-point expanded disability status scale change (entry expanded disability status scale, 5.5-6.5) sustained for 3 months. The trial was stopped after an interim analysis by an independent data safety monitoring board indicated no discernible treatment effect on the primary outcome. Intention-to-treat analyses of disability and magnetic resonance imaging end points were performed. RESULTS: There was a nonsignificant delay in time to sustained accumulated disability in GA- versus PBO-treated patients (hazard ratio, 0.87 [95% confidence interval, 0.71-1.07]; p = 0.1753), with significant decreases in enhancing lesions in year 1 and smaller increases in T2 lesion volumes in years 2 and 3 versus PBO. Post hoc analysis showed that survival curves for GA-treated male patients diverged early from PBO-treated male subjects (hazard ratio, 0.71 [95% confidence interval, 0.53-0.95]; p = 0.0193). INTERPRETATION: The trial failed to demonstrate a treatment effect of GA on primary progressive multiple sclerosis. Both the unanticipated low event rate and premature discontinuation of study medication decreased the power to detect a treatment effect. Post hoc analysis suggests GA may have slowed clinical progression in male patients who showed more rapid progression when untreated.
|
Authors | Jerry S Wolinsky, Ponnada A Narayana, Paul O'Connor, Patricia K Coyle, Corey Ford, Kenneth Johnson, Aaron Miller, Lillian Pardo, Shaul Kadosh, David Ladkani, PROMiSe Trial Study Group |
Journal | Annals of neurology
(Ann Neurol)
Vol. 61
Issue 1
Pg. 14-24
(Jan 2007)
ISSN: 0364-5134 [Print] United States |
PMID | 17262850
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Chemical References |
- Immunosuppressive Agents
- Peptides
- Glatiramer Acetate
|
Topics |
- Adult
- Disability Evaluation
- Double-Blind Method
- Female
- Follow-Up Studies
- Glatiramer Acetate
- Humans
- Immunosuppressive Agents
(therapeutic use)
- International Cooperation
- Male
- Middle Aged
- Multiple Sclerosis, Chronic Progressive
(drug therapy)
- Peptides
(therapeutic use)
- Proportional Hazards Models
- Retrospective Studies
- Severity of Illness Index
- Sex Factors
|